Zydus Cadila gets USFDA approval to market Topiramate Capsules

27 Nov 2017 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules in the strengths of 25 mg, 50 mg, and 100 mg. The drug is indicated for the treatment of seizures and migraine headaches. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 170 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

900.25 5.25 (0.59%)
13-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.80
Dr. Reddys Lab 1190.35
Cipla 1447.60
Zydus Lifesciences 900.25
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×